William Nwachukwu
Datos Biográficos
| ID | 9020487 |
|---|---|
| NOMBRE | William Nwachukwu |
| NOMBRES | William |
| APELLIDO | Nwachukwu |
| FIRMA | NWACHUKWU W |
| AFILIACIONES | Nigeria Centre for Disease Control |
| ORCID | 0000-0001-7111-1320 |
| VERIFICADO | Sí |
| TOTAL DE OBRAS | 6 |
| TOTAL DE CITAS | 0 |
| TOTAL COMO AUTOR | 6 |
| TOTAL COMO EDITOR | 0 |
| PRIMER AÑO DE PUBLICACIÓN | 2020 |
| AÑO MÁS RECIENTE DE PUBLICACIÓN | 2025 |
| ÍNDICE H | 0 |
Field validation and application of the luminex triplex HIV assay to estimate HIV prevalence and HIV-1 incidence in Nigeria
HIV cross-sectional surveys require multi-layered testing with several tests to estimate HIV prevalence and HIV-1 incidence. We evaluated the performance and accuracy of the newly developed HIV Triplex assay to diagnose HIV-1 and HIV-2 and detect HIV-1 recent infections using plasma samples from the 2018 Nigeria AIDS Indicator and Impact Survey (NAIIS). Plasma samples from consenting HIV-positive (n=2,773) and a subset of HIV-negative samples (n=…
Seroprevalence of Sars-CoV-2 in four states of Nigeria in October 2020
The observed epidemiology of SARS-CoV-2 in sub-Saharan Africa has varied greatly from that in Europe and the United States, with much lower reported incidence. Population-based studies are needed to estimate true cumulative incidence of SARS-CoV-2 to inform public health interventions. This study estimated SARS-CoV-2 seroprevalence in four selected states in Nigeria in October 2020. We implemented a two-stage cluster sample household survey in fo…
Covid-19 mortality rate and its associated factors during the first and second waves in Nigeria
COVID-19 mortality rate has not been formally assessed in Nigeria. Thus, we aimed to address this gap and identify associated mortality risk factors during the first and second waves in Nigeria. This was a retrospective analysis of national surveillance data from all 37 States in Nigeria between February 27, 2020, and April 3, 2021. The outcome variable was mortality amongst persons who tested positive for SARS-CoV-2 by Reverse-Transcriptase Poly…
Covid-19 vaccine effectiveness studies in Nigeria
The “lickety–split” development of COVID-19 vaccines 326 days from when the SARS-COV-2 virus was first sequenced is indeed one of the public health successes of the 21st century. Particularly because an 18-month target was initially considered reasonable, and having achieved this success, a “moonshot” goal to ensure that a vaccine is available within 100 days [...]
Epidemiological comparison of the first and second waves of the Covid-19 pandemic in Nigeria, February 2020–April 2021
BACKGROUND: With reports of surges in COVID-19 case numbers across over 50 countries, country-level epidemiological analysis is required to inform context-appropriate response strategies for containment and mitigation of the outbreak. We aimed to compare the epidemiological features of the first and second waves of COVID-19 in Nigeria. METHODS: We conducted a retrospective analysis of the Surveillance Outbreak Response Management and Analysis Sys…
Nigeria’s public health response to the Covid-19 pandemic
The novel coronavirus disease 2019, COVID-19, which is caused by severe acute respiratory syndrome \nvirus 2 (SARS-CoV-2) [1] was first reported in December 2019 by Chinese Health Authorities following an outbreak of pneumonia of unknown origin in Wuhan, Hubei Province [2,3]. SARS-CoV-2 is \nlikely of zoonotic origin, similar to SARS and Middle East Respiratory Syndrome (MERS), and transmitted between humans through respiratory droplets and fomit…
Sin obras prominentes en esta página.
Nigeria’s public health response to the Covid-19 pandemic
The novel coronavirus disease 2019, COVID-19, which is caused by severe acute respiratory syndrome \nvirus 2 (SARS-CoV-2) [1] was first reported in December 2019 by Chinese Health Authorities following an outbreak of pneumonia of unknown origin in Wuhan, Hubei Province [2,3]. SARS-CoV-2 is \nlikely of zoonotic origin, similar to SARS and Middle East Respiratory Syndrome (MERS), and transmitted between humans through respiratory droplets and fomit…
Epidemiological comparison of the first and second waves of the Covid-19 pandemic in Nigeria, February 2020–April 2021
BACKGROUND: With reports of surges in COVID-19 case numbers across over 50 countries, country-level epidemiological analysis is required to inform context-appropriate response strategies for containment and mitigation of the outbreak. We aimed to compare the epidemiological features of the first and second waves of COVID-19 in Nigeria. METHODS: We conducted a retrospective analysis of the Surveillance Outbreak Response Management and Analysis Sys…
Seroprevalence of Sars-CoV-2 in four states of Nigeria in October 2020
The observed epidemiology of SARS-CoV-2 in sub-Saharan Africa has varied greatly from that in Europe and the United States, with much lower reported incidence. Population-based studies are needed to estimate true cumulative incidence of SARS-CoV-2 to inform public health interventions. This study estimated SARS-CoV-2 seroprevalence in four selected states in Nigeria in October 2020. We implemented a two-stage cluster sample household survey in fo…
Covid-19 mortality rate and its associated factors during the first and second waves in Nigeria
COVID-19 mortality rate has not been formally assessed in Nigeria. Thus, we aimed to address this gap and identify associated mortality risk factors during the first and second waves in Nigeria. This was a retrospective analysis of national surveillance data from all 37 States in Nigeria between February 27, 2020, and April 3, 2021. The outcome variable was mortality amongst persons who tested positive for SARS-CoV-2 by Reverse-Transcriptase Poly…
Covid-19 vaccine effectiveness studies in Nigeria
The “lickety–split” development of COVID-19 vaccines 326 days from when the SARS-COV-2 virus was first sequenced is indeed one of the public health successes of the 21st century. Particularly because an 18-month target was initially considered reasonable, and having achieved this success, a “moonshot” goal to ensure that a vaccine is available within 100 days [...]
Field validation and application of the luminex triplex HIV assay to estimate HIV prevalence and HIV-1 incidence in Nigeria
HIV cross-sectional surveys require multi-layered testing with several tests to estimate HIV prevalence and HIV-1 incidence. We evaluated the performance and accuracy of the newly developed HIV Triplex assay to diagnose HIV-1 and HIV-2 and detect HIV-1 recent infections using plasma samples from the 2018 Nigeria AIDS Indicator and Impact Survey (NAIIS). Plasma samples from consenting HIV-positive (n=2,773) and a subset of HIV-negative samples (n=…
Internal Medicine (6 obras) · Medicine (6 obras) · COVID-19 epidemiological studies (4 obras) · Virology (4 obras) · Demography (3 obras) · Environmental health (3 obras) · Outbreak (3 obras) · Pandemic (3 obras) · 2019-20 coronavirus outbreak (2 obras) · Antibody (2 obras)